CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report)'s stock had its "buy" rating restated by equities researchers at Needham & Company LLC in a report released on Thursday,Benzinga reports. They presently have a $81.00 price objective on the stock. Needham & Company LLC's price target indicates a potential upside of 73.91% from the company's current price.
CRSP has been the subject of several other research reports. HC Wainwright reiterated a "buy" rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. JMP Securities restated a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, May 21st. Wall Street Zen raised CRISPR Therapeutics to a "sell" rating in a research note on Friday, May 16th. The Goldman Sachs Group reduced their price objective on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Finally, Chardan Capital restated a "buy" rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a report on Thursday. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $69.53.
Get Our Latest Stock Report on CRSP
CRISPR Therapeutics Stock Performance
NASDAQ:CRSP traded down $1.09 during midday trading on Thursday, reaching $46.58. 1,058,653 shares of the stock traded hands, compared to its average volume of 2,223,991. The stock has a market capitalization of $4.02 billion, a P/E ratio of -10.30 and a beta of 1.75. The company has a fifty day moving average of $39.10 and a 200 day moving average of $40.58. CRISPR Therapeutics has a 12 month low of $30.04 and a 12 month high of $63.68.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. CRISPR Therapeutics's quarterly revenue was up 71.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.43) EPS. On average, analysts predict that CRISPR Therapeutics will post -5.16 EPS for the current fiscal year.
Insider Activity at CRISPR Therapeutics
In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the firm's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the completion of the transaction, the insider now owns 6,068 shares of the company's stock, valued at approximately $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.30% of the stock is currently owned by corporate insiders.
Institutional Trading of CRISPR Therapeutics
Hedge funds have recently made changes to their positions in the stock. SVB Wealth LLC bought a new position in CRISPR Therapeutics during the 1st quarter valued at approximately $25,000. Costello Asset Management INC purchased a new stake in shares of CRISPR Therapeutics in the first quarter worth $27,000. Wood Tarver Financial Group LLC purchased a new stake in shares of CRISPR Therapeutics in the fourth quarter worth $30,000. Ameriflex Group Inc. bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at $36,000. Finally, Quantbot Technologies LP increased its holdings in shares of CRISPR Therapeutics by 272.4% during the first quarter. Quantbot Technologies LP now owns 1,337 shares of the company's stock valued at $45,000 after acquiring an additional 978 shares in the last quarter. 69.20% of the stock is owned by institutional investors.
CRISPR Therapeutics Company Profile
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
